Rituximab Monoclonal Antibody: Mechanisms of Action Against B-Cell Lymphoma

Description

This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication. This template depicts the four mechanisms of action of the monoclonal antibody Rituximab against CD20-expressing B-cells. Following Rituximab binding to CD20, B-cell may undergo: direct killing mediated by Natural Killer cells, complement-mediated cytotoxicity that leads to cell lysis, antibody-dependent cell cytotoxicity mediated by perforin and granzime cytokines, and antibody-dependent phahocytosis performed by activated macrophages.

Acknowledgements

References

Timothy M. Pierpont (2018). Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Front. Oncol. Zhou, X et. al.. (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.. Oncologist. https://pubmed.ncbi.nlm.nih.gov/18779537/

Get started with this template for free

Don’t start from scratch.

Create professional scientific illustrations quickly and easily, even without any design expertise

Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
Create figures that effectively communicate your research in half the time using our editable icons.
Use our PDB tool to quickly generate and customize protein structures

Get started now